Delivery Order SPE2DB22D1202-SPE2DB25FVJV5
- Not listed
- The Defense Logistics Agency awarded a $2,886.90 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Verquvo 2.5 mg tablets (30-count units). This firm fixed price, non-set-aside contract is expected to be completed by August 18, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $3,721.73 to AmerisourceBergen Drug Corp for Verquvo 5 mg tablets (14-count packaging) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order is non-set-aside and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this requirement as...
- The Defense Logistics Agency awarded a $1,849.00 delivery order to AmerisourceBergen Drug Corp for VERQUVO 2.5 mg tablets (30 count) on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,080.72, is for the delivery of the medication Verquvo 2.5 mg tablet, with a performance period through May 2, 2025. This is a firm fixed-price delivery order contract, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,284.74 firm fixed-price delivery order is for the supply of 90 tablets of the medication VERQUVO 10 MG. The contract has an ultimate completion date of May 9, 2025 and is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract...
- This federal contract award, valued at $2,854.78, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VERQUVO 5 MG TABLET 30S, a pharmaceutical product, and has an ultimate completion date of June 10, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. The contract was not designated with a set-aside requirement, indicating open...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,532.49 delivery order contract is for the supply of the prescription medication VERQUVO 10 MG TABLET 30S. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 11, 2025. This award is not designated as a set-aside contract, indicating open competition. AmerisourceBergen Drug...
- This federal contract award to Amerisourcebergen Drug Corp., a subsidiary of Amerisourcebergen Corporation, provides for the delivery of the pharmaceutical product VERQUVO 5 MG TABLET 30S to the Defense Logistics Agency (DLA). The contract is a Delivery Order with a Firm Fixed Price of $2,438.25 and has an ultimate completion date of May 10, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth up to $999,999,999.00 through December...
- This federal contract award is a delivery order valued at $3,501.47 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of VERQUVO 2.5 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of November 1, 2024 and is a firm fixed price arrangement. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,467.93 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the U.S. Department of Defense. The contract is for the supply of VERQUVO 2.5 MG TABLET 30S, a pharmaceutical product, with a period of performance through May 22, 2024. AmerisourceBergen holds a significant $999,999,999...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVJV5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Verquvo 5 mg tablets (30-count package) with a ceiling value of $1,052.64 and firm fixed pricing. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for the Defense Logistics Agency. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency and its Medical Supply Chain. The company's federal contract portfolio demonstrates extensive capability in supplying a broad spectrum of pharmaceutical products and medical supplies, ranging from brand-name and generic medications to specialized healthcare commodities across multiple therapeutic domains. All of the company's reviewed federal contract awards have been competitively awarded without set-aside designations, and the DLA is planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen to serve customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/29/25 |